S
Sonia M. Davis
Researcher at University of North Carolina at Chapel Hill
Publications - 80
Citations - 19288
Sonia M. Davis is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Antipsychotic & Risperidone. The author has an hindex of 49, co-authored 80 publications receiving 18120 citations. Previous affiliations of Sonia M. Davis include North Carolina Department of Health and Human Services & Harvard University.
Papers
More filters
Journal ArticleDOI
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Jeffrey A. Lieberman,T. Scott Stroup,Joseph P. McEvoy,Joseph P. McEvoy,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Richard S.E. Keefe,Sonia M. Davis,C.E. Davis,Barry D. Lebowitz,Joanne B. Severe,John K. Hsiao +12 more
TL;DR: Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.
Journal ArticleDOI
Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
Joseph P. McEvoy,Jonathan M. Meyer,Donald C. Goff,Henry A. Nasrallah,Sonia M. Davis,Lisa M. Sullivan,Herbert Y. Meltzer,John K. Hsiao,T. Scott Stroup,Jeffrey A. Lieberman +9 more
TL;DR: The metabolic syndrome is highly prevalent in US schizophrenia patients and represents an enormous source of cardiovascular risk, especially for women, so clinical attention must be given to monitoring for this syndrome, and minimizing metabolic risks associated with antipsychotic treatment.
Journal ArticleDOI
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Lon S. Schneider,Pierre N. Tariot,Karen S. Dagerman,Sonia M. Davis,John K. Hsiao,M. Saleem Ismail,Barry D. Lebowitz,Constantine G. Lyketsos,J. Michael Ryan,T. Scott Stroup,David L. Sultzer,Daniel Weintraub,Jeffrey A. Lieberman +12 more
TL;DR: Adverse effects offset advantages in the efficacy of atypical antipsychotic drugs for the treatment of psychosis, aggression, or agitation in patients with Alzheimer's disease.
Journal ArticleDOI
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Richard S.E. Keefe,Robert M. Bilder,Sonia M. Davis,Philip D. Harvey,Barton W. Palmer,James M. Gold,Herbert Y. Meltzer,Michael F. Green,George Capuano,T. Scott Stroup,Joseph P. McEvoy,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Clarence E. Davis,John K. Hsiao,Jeffrey A. Lieberman +16 more
TL;DR: After 2 months of antipsychotic treatment, all groups had a small but significant improvement in neurocognition, and after 18 months of treatment, neurocognitive improvement was greater in the perphenazine group than in the olanzapine and risperidone groups.
Journal ArticleDOI
Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment
Joseph P. McEvoy,Jeffrey A. Lieberman,T. Scott Stroup,Sonia M. Davis,Herbert Y. Meltzer,Robert A. Rosenheck,Marvin S. Swartz,Diana O. Perkins,Richard S.E. Keefe,Clarence E. Davis,Joanne B. Severe,John K. Hsiao +11 more
TL;DR: For patients with schizophrenia who prospectively failed to improve with an atypical antipsychotic, clozapine was more effective than switching to another newer atypicals antipsychotics.